Agenda
6:00PM to 6:30PM Registration
6:30PM to 6:35PM Welcome and Opening Remarks
6:35PM to 7:00PM Overview of Diabetes Technology
7:00PM to 7:25PM Identifying and Overcoming Barriers to the Use of Diabetes Technology
7:25PM to 7:45PM Patient Engagement and Implementation in to Care
7:45PM to 8:00PM Questions and Answers
Events
Date / Time
Event Details
Faculty
Faculty
Andrew Bzowyckyi, PharmD, BCPS, CDCES
Associate Professor
School of Pharmacy
Pacific University Oregon
Hillsboro, Oregon
Clinic Pharmacist
Legacy Medical Group Cornell
Beaverton, Oregon
Faculty
Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP
Endocrine Clinical Pharmacy Specialist
CGM and Remote Monitoring Program Coordinator
Endocrinology and Metabolism Institute
Cleveland Clinic
Cleveland, Ohio
Program Overview
This program will provide expert insights on integration of available diabetes technologies, strategies to overcome barriers to implementation as well as how to engage and educate patients on appropriate use to improve diabetes outcomes.
Goal Statement
The goal of this activity is to improve the knowledge and competence of pharmacists about how current and emerging digital technology within diabetes care can improve glycemic control and how to best implement its use in clinical practice.
Target Audience
The target audience for this activity is pharmacists, including community, ambulatory care, primary care, and clinical pharmacists, who care for patients with diabetes who would benefit from diabetes technology and pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate new and emerging diabetes technologies, including their role in reducing A1C, hypoglycemia, postprandial hyperglycemia, and improving time in range
- Identify methods to overcome potential barriers to incorporating CGM or insulin-delivery devices into the care of a patient with diabetes
- Discuss the role of the pharmacist in utilization of diabetes technologies in practice, including patient engagement and education, shared decision-making, and counseling patients on how diabetes technology can improve adherence and glycemic outcomes
Accreditation
CE Accreditation
Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-094-L01-P has been assigned to this live application-based activity (initial release date 3-19-22). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.